Physician profile
Chevita Fuller
NPI 1437521028
$4,040.76
in general payments reported to CMS, 2019-2025
31 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $745 · 2023: $377 · 2024: $1,052 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.59 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $538.34 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $486.63 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $376.05 | 2022-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $358.83 | 2021-2025 | Nucala, Arexvy, Shingrix |
| Pfizer INC. | $268.73 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $255.61 | 2022-2025 | |
| Scpharmaceuticals INC. | $219.41 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $219.30 | 2021-2025 | Verquvo |
| Amgen INC. | $200.51 | 2021-2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $142.64 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $119.06 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $80.61 | 2021-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $72.68 | 2021-2024 | |
| Medicomp INC | $72.14 | 2022 | |
| Alnylam Pharmaceuticals INC. | $70.14 | 2021-2025 | Amvuttra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.53 | 2021 | |
| Daiichi Sankyo INC. | $54.16 | 2024 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $50.73 | 2024 | Arcalyst |
| Abbott Laboratories | $45.70 | 2022 | |
| Boston Scientific Corporation | $43.14 | 2022-2025 | Watchman Flx |
| Abiomed | $42.16 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.61 | 2022-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $39.28 | 2022-2025 | Opsumit, Uptravi |
| Vital Connect, INC | $33.82 | 2023 | Vitalpatch Rtm |
| Philips North America LLC | $27.59 | 2025 | Extended Holter |
| Inspire Medical Systems, INC. | $27.08 | 2025 | Inspire |
| Cvrx, INC. | $24.16 | 2024 | Barostim Neo System |
| G Medical Diagnostic Services, INC. | $24.03 | 2022 | |
| Biotronik INC. | $20.07 | 2024 | Orsiro Mission, Nhancer Rx |
| Esperion Therapeutics, INC. | $15.71 | 2025 | Nexletol |
| Vivaquant INC, Dba Rhythm Express | $7.31 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chevita Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.